![\"](\"https:\/\/i-base.info\/wp-content\/uploads\/2016\/10\/R4P2016-logo-1-271x300.png\"){kind=logo}
<\/p>\n<\/p>\n
Simon Collins, HIV i-Base<\/strong><\/p>\n A study reporting that low TDF\/FTC concentrations in breastmilk do not put a baby at risk will be important in enabling women to routinely use PrEP irrespective of whether or not they are breastfeeding.<\/strong><\/p>\n Kenneth Mugwanya from University of Washington presented results from a pharmacokinetic study in 50 mother and infant pairs. The mothers were given daily PrEP for ten days with drugs levels measured in both breast milk samples and infant plasma samples. [1]<\/p>\n Median age of the infants was 13 weeks.<\/p>\n Only very small quantities of tenofovir (median med 0.2 ng\/mL) transferred to milk – approximately at 3% of blood levels in the mothers. Tenofovir was not quantifiable in 94% of infant plasma samples. Based on the milk concentration, the infants had TFV exposures at less than 0.01% of the proposed infant therapeutic dose (6 mg\/kg).<\/p>\n Emtricitabine (FTC) concentrations in breast milk were also low, although somewhat higher (median 212.5 ng\/mL). These concentrations were consistent with those seen with 3TC, abacavir and AZT. Overall, 47\/49 samples had detectable FTC in infant plasma, but at small concentrations (13.2 ng\/mL), equivalent to approximately 0.5% of the proposed therapeutic infant dose.<\/p>\n Even though this was a small study, it provides the first data to suggest that PrEP can be safely used by women who are breastfeeding.<\/p>\n Full results from the study were published as an open access paper in PLoS Medicine in September 2016. [2]<\/p>\n References:<\/p>\n Simon Collins, HIV i-Base A study reporting that low TDF\/FTC concentrations in breastmilk do not put a baby at risk will be important in enabling women to routinely use PrEP irrespective of whether or not they are breastfeeding. Kenneth Mugwanya …<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4,35,10],"tags":[234],"class_list":["post-30815","post","type-post","status-publish","format-standard","hentry","category-conference-reports","category-pmtct-and-maternal-health","category-transmission-and-prevention","tag-r4p-2016-chicago"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/30815","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=30815"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/30815\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=30815"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=30815"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=30815"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}\n
\nhttp:\/\/journals.plos.org\/plosmedicine\/article?id=10.1371\/journal.pmed.1002132<\/a><\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"